Cedars-Sinai plays key role in investigation of Iressa

May 05, 2003

The Food and Drug Administration announced approval today for Iressa, a new drug that shrinks tumors in about 10 percent of patients whose lung cancer has progressed despite two prior rounds of standard chemotherapy. Iressa, taken daily in pill form, is the first of a new class of drugs that works by targeting and blocking key growth signals in cancer cells.

Physician: Ronald Natale, M.D., the Principal Investigator on the clinical trial at Cedars-Sinai Medical Center, Acting Medical Director at Cedars-Sinai Comprehensive Cancer Center and National Program Director for Lung Cancer for Salick Health Care, Inc., is available for media interviews. A patient who participated in the study at the Cedars-Sinai Comprehensive Cancer Center and testified before the FDA's Oncologic Drug Advisory Committee is also willing to be interviewed.

Patient :
Susan Nelson of Perris, California is a School Teacher. A non-smoker, Susan was first diagnosed with a slow-growing lung cancer called bronchoalveolar carcinoma in 1989. Her treatment began with surgery to remove a portion of her right lung and, after her cancer recurred in 1994, she was told that her only option was a heart and lung transplant. Instead, Susan decided not to pursue that treatment option, but by August 2001, the cancer had returned, forming a large mass in each lung. At that point, she enrolled in a clinical trial testing the effectiveness of Iressa and her condition has improved considerably.

The FDA granted approval for Iressa as a treatment of last resort for patients who had failed two or more types of chemotherapy - despite findings that treatment with a combination of Iressa and chemotherapy failed to improve survival for newly diagnosed lung cancer patients. Because Iressa is a drug that targets specific protein molecules expressed on cancer cells, it does not have the side effects typical of treatment with chemotherapy.

Non-small-cell lung cancer is the most common type of lung cancer, a disease that kills about 155,000 Americans each year. Typically, non-small-cell lung cancer is treated with surgery followed by chemotherapy and/or radiation. But because lung cancer is usually diagnosed in its advanced stages, these treatments rarely bring about a cure, with side effects often outweighing any benefits.
The Cedars-Sinai Comprehensive Cancer Center is managed by a subsidiary of Salick Health Care, Inc. Salick Health Care, Inc. is an independently operated subsidiary of AstraZeneca.

To schedule an interview, please contact Kelli Stauning at 310-423-3674 or via e-mail at kelli.stauning@cshs.org.

Cedars-Sinai Medical Center

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.